Language:
Daily summary of financings for therapeutic biotechnology company executives and investors
Thursday, February 5, 2026
Angitia’s $130 Million Series D
LB’s $100 Million Private Placement
Wednesday, February 4, 2026
Chamber’s $60 Million Series A
Third Arc’s $52 Million Series A
Tuesday, February 3, 2026
Veradermics’s $256 Million IPO
Adlai’s $140 Million Private Placement
Sangamo’s $25 Million Public Offering
SonoVascular ‘s $6 Million Series A
Monday, February 2, 2026
Vaxcyte’s $632 Million Public Offering…More
Friday, January 30, 2026
ProMIS’s $175 Million Private Placement
ALX’s $150 Million Public Offering
Lexicon’s $42 Million Public Offering and $53 Million Private Placement
Scilex’s $20 Million Equity Investment
Coya’s $11 Million Private Placement
Thursday, January 29, 2026
Breakthru’s $60 Million Series A
Prenosis’s $20 Million Series A
Aprea’s $6 Million Private Placement
Rakovina’s $1 Million Debt Financing
Enveric’s $1 Million Registered Direct Offering
Wedesday, January 28, 2026
Cellares’s $257 Million Series D
Veradermics’s $200 Million IPO
Sensorion’s $72 Million Private Placement
CraniUS’s $20 Million Series B
Elysium’s $7 Million Fund Raise
Biomind’s $2 Million Private Placement
Tuesday, January 27, 2026
Epidarex’s $145 Million Fund Raise
Insilico’s $120 Million Venture Financing
Savara’s $75 Million Debt Financing
Altimmune’s $75 Million Registered Direct Offering
TRexBio’s $50 Million Venture Financing
BridGene’s $28 Million Series B+
Monday, January 26, 2026
Mirum’s $268 Million Acquisition of Bluejay
Fortitude’s $13 Million Seed Round…More
Barnwell’s $6 Million Seed Round
Friday, January 23, 2026
Thursday, January 22, 2026
CORXEL’s $287 Million Series D1

Axogen’s $124 Million Public Offering
Wednesday, January 21, 2026
Erasca’s $225 Million Public Offering…More
BioAge’s $115 Million Public Offering
Infinitopes’s $35 Million Seed Round
Ocugen’s $22 Million Public Offering
ErVimmune’s $20 Million Series A
BIOMAKERS’s $8 Million Fund Raise
L-Nutra’s $36 Million Series D
Tuesday, January 20, 2026
GSK $2.2B Acquisition of RAPT Therapeutics
enGene’s $125 Million Debt Financing
4DMedical $100 Million Private Placement
Think Bioscience’s $55 Million Series A
Friday, January 16, 2026
BridgeBio’s $550 Million Debt Financing
DBV’s $196 Million Warrant Exercise
Cytotheryx’s $60 Million Series A
Cardiol’s $13 Million Private Placement
Tiziana’s $9 Million Registered Direct Offering
MetaVia’s $9 Million Public Offering…More
Vivos’s $5 Million Warrant Exercise
Thursday, January 15, 2026
Boston Scientific’s $14 Billion Acquisiton of Penumbra
Agenus’s $141 Million Venture Financing
BriaCell’s $30 Million Public Offering
Wednesday, January 14, 2026
Caldera’s $112 Million Series A-1
Plus’s $15 Million Public Offering
Beyond’s $5 Million Private Placement
Tuesday, January 13, 2026
Nuclera’s $87 Million Series C
Proxima’s $80 Million Seed Round
Pelthos’s $50 Million Debt Financing
Foghorn’s $50 Million Registered Direct Offering
BriaCell’s $30 Million Public Offering
Converge’s $25 Million Series A
Vivere’s $10 Million Fund Raise
Enspire’s $10 Million Series B1
Monday, January 12, 2026
Recludix’s $123 Million Equity Financing
Precede’s $83 Million Series B
Oricell’s $70 Million Series C
Vibrant’s $61 Million Series B
Trailhead’s $40 Million Fund Raise
Dogwood’s $27 Million Registered Direct Offering
OutSee’s $3 Million Seed Round
Saturday, January 10, 2026
Kinaset’s $103 Million Series B
Friday, January 9, 2026
Haemonetics’s $215 Million Acquisition of Vivasure
AirNexis’s $200 Million Series A
Medipost’s $140 Million Fund Raise
Curis’s $81 Million Private Placement
Aptevo’s $60 Million Equity Investment
Clene’s $28 Million Registered Direct Offering
iBio $26 Million Private Placement
Aurora’s $16 Million Seed Round
Thursday, January 8, 2026
Lily’s $1.2Billion Acquisition of Ventyx
Parabilis $305Million Series F
Monte Rosa’s $300 Million Public Offering
Alveus’s $160 Million Series A
Century’s $135 Million Private Placement
SonoThera’s $125 Million Series B
Diagonal’s $125 Million Series B
EpiBiologics’s $107 Million Series B
Spruce’s $50 Million Debt Financing
Vizgen’s $48 Million Venture Financing
32 Biosciences’s $40 Million Series A
Engitix’s $25 Million Series A
Enodia’s $24 Million Fund Raise
Genelux’s $20 Million Public Offering…More
Wednesday, January 7, 2026
InduPro’s $950 Million Merger with Lilly
Arrowhead’s $500 Million Debt Financing
Soley’s $200 Million Series C
Bright Minds’s $175 Million Public Offering
Phathom’s $130 Million Public Offering
Collabrity Report 2025 – 2026,
All Rights Reserved
Please note that we exclusively feature news related to Biotech Financing.
Securities are offered through Finalis Securities LLC Member FINRA / SIPC. Collabrity is not a registered broker-dealer, and Finalis Securities LLC and Collabrity are separate, unaffiliated entities. Finalis Securities LLC, Office of Supervisory Jurisdiction is located at 450 Lexington Ave, New York, NY 10017, 800-962-0418.
Finalis Privacy Policy | Finalis Business Continuity Plan | FINRA BrokerCheck | Finalis Form Customer Relationship Summary (“Form CRS”)
collabrityreport.com (the “Collabrity Report Website”) is a website operated by Collabrity. This website is for informational purposes only, is not an offer, solicitation, recommendation, or commitment for any transaction or to buy or sell any security or other financial product, and is not intended as investment advice or as a confirmation of any transaction. Products and services on this website may not be available for residents of certain jurisdictions. Please consult with a Finalis Securities’ registered representative regarding the product or service in question for further information. Investments involve risk and are not guaranteed to appreciate. Any market price, indicative value, estimate, view, opinion, data, or other information herein is not warranted as to completeness or accuracy, is subject to change without notice, and Collabrity along with Finalis Securities LLC accepts no liability for its use or to update it or keep it current.
Investing in private placements involves a high degree of risk. These investments may be illiquid, speculative, and subject to substantial restrictions on transferability. Investors may lose all or part of their investment and should only invest capital they can afford to lose. Prospective investors should conduct their own due diligence and consult with their legal, tax, and financial advisors prior to making any investment decision. For your reference, Finalis’ Form CRS describes the services that we provide, how we are compensated, and other important information about Finalis Securities LLC.